Abstract. Although endocrine disrupting chemicals (EDCs) may interfere with the endocrine system(s) of our body and have estrogenicity or androgenicity, the exact mechanism(s) underlying their detrimental effects is not clearly understood. Thus, in this study, we evaluated the effects of EDCs on proliferation and regulation of transcription of estrogen receptor (ER)-positive BG-1 ovarian cancer cells, and their possible mechanisms were further examined. Treatment with bisphenol A (BPA), nonylphenol (NP), octylphenol (OP) and methoxychlor (MXC) for 24 h resulted in an increase of cell proliferation. Treatment with BPA, NP, OP and MXC increased the estrogen response element (ERE) activity. The increase of cell proliferation and activation of ERE were reversed in the presence of an estrogen receptor antagonist, ICI 182780. These results suggest that ER is involved in EDC-mediated pathway in ovarian cancer cells. Based on this, we further investigated the involvement of EDCs in activation of mitogen-activated protein kinase (MAPK) in relation to cell growth. BPA rapidly induced activation of extracellular signal-regulated kinase (ERK) 1/2 and p38 MAPK at 15 min, but the effect of BPA (10 μM) on stimulation of cell growth was not blocked by pretreatment with inhibitors of MEK (PD98059) or p38 (SB203580) in a dose-dependent manner. Taken together, EDC-induced proliferation is mediated by a genomic effect through ERs and ERE, but EDC-activated MAPK is unlikely to be involved in EDC-induced cell growth in estrogen-responsive ovarian cancer cells. Key words: Endocrine disrupting chemical, Estrogen receptor, Estrogen response element, Extracellular signalregulated kinase, Mitogen-activated protein kinase (J. Reprod. Dev. 55: [23] [24] [25] [26] [27] [28] [29] 2009) varian carcinoma is one of the most frequent gynaecologic cancers, following breast, lung and colorectal cancer [1] . Although the biological causes of ovarian cancer remain unknown, hormonal factors such as estrogen or gonadotropins have been implicated in the etiology of ovarian cancer [2] . In addition, it has been reported that endocrine disrupting chemicals (EDCs) may increase the risk of cancer incidence [3, 4] . However, the data associated with the effect of EDCs on ovarian cancer cells are scarce.
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Since EDCs are known as environmental chemicals that interfere with the hormonal balance of vertebrates and invertebrates, they are considered to be important in physiology and the endocrine system [5, 6] . EDCs are released from industrial products such as plastics, pesticides, detergents and other synthetic products. It has been proposed that EDCs may increase human health risks and have potentials to affect the immune system and development of vital organs [7] [8] [9] .
Bisphenol-A (BPA), alkylphenols, dichloro-diphenyl-trichloroethane (DDT), polychlorinated biphenyls (PCBs) and phthalates are mainly highlighted among EDCs. BPA, a compound used in polycarbonate and epoxy resins, has been implicated as a potent risk factor for women's health [10] . BPA has been widely used in plastic products, such as drinking water containers, dental sealants and coating materials to prevent corrosion on the inner surfaces of metal food containers, and is released from plastic containers under normal conditions of use; the leaching of BPA is facilitated by high temperatures [11] . Exposure to BPA is even possible by contact with swallowed dust [12] , and even this type of exposure exerts xenoestrogen action [13] . Methoxychlor (MXC), a synthetic pesticide, has been used as a replacement for DDT and is considered to be a xenoestrogen that disrupts the reproductive system [14] . In addition, 4-alkylphenol ethoxylates (APEs) are widely used as surfactants in lubricant oil addictives, phosphate antioxidants and rubber products [15] , and they have been shown to have an estrogenic effect [16] . Furthermore, the metabolites of APEs, such as nonylphenol (NP) and octylphenol (OP), exhibit an estrogenic effect at low concentrations [5, 17] . They are known as toxic contaminants and can be found in indoor/outdoor air and in the aquatic environment [18, 19] . Based on these previous studies, we further examined the effects of EDCs on cell proliferation and the activation of estrogen response element (ERE) in an E2-dependent ovarian cancer cell line, BG-1. In addition, possible mechanisms of EDCs involved in cell proliferation were subsequently investigated.
Materials and Methods

Cells and cell culture
BG-1 and A2780 human ovarian cancer cells were provided by Dr. KS Korach (National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA) and obtained from ECACC (Porton Down, UK), respectively. Cells were cultured in DMEM/F12 mixture (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% FBS (HyClone, Logan, UT, USA), 100 U/ml penicillin G and 100 μg/ml streptomycin (Life Technologies, Rockville, MD, USA) at 37 C in a humidified atmosphere of 5% CO2-95% air.
Preparation of plasmid constructs
The reporter plasmid ERE2-tk109-Luc was provided by Dr. JL Jameson (Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, IL, USA) as previously used [20] . The study of transfection was performed using plasmid DNAs prepared using Plasmid Maxi Kits (Qiagen, Chatsworth, CA, USA) following the manufacturer's suggested procedure. The concentration of DNA was measured by absorbance at 260 nm, and the integrity of plasmid DNA was determined by agarose gel electrophoresis. Purified plasmid DNAs were then dissolved 0.1 × TE (1 mM Tris-Cl; pH 7.5, 0.1 mM EDTA).
Transient transfection and reporter assay
Transient transfection was performed using FuGENE 6.0, according to the manufacturer's procedure (Roche Diagnostics, Laval, Quebec, Canada). To correct for the different transfection efficiencies of various luciferase constructs, the Rous sarcoma virus (RSV)-lacZ plasmid was co-transfected into the cells. BG-1 cells were seeded at a density of 4 × 10 5 into six-well tissue culture plates in 2 ml phenol red-free DMEM (Life Technologies) containing 10% charcoal-dextran-treated FBS (HyClone) before the day of transfection. One μg of the ERE promoter-luciferase construct, 0.5 μg RSV-lacZ and an indicated amount of expression plasmids were dissolved in 100 μl phenol red-free DMEM containing 3 μl FuGENE 6.0. The DNA mixture was incubated for 45 min at room temperature and then applied to the cells. Incubation of the cells with transfection medium continued for approximately 24 h at 37 C in 5% CO2. After 24-h transfection, the cells were treated with various concentrations of 17β-estradiol (E2), BPA, MXC, OP, or NP at different time concentrations before harvest. Ethanol was added to the control media at the same final solvent concentration (typically 0.1%). The cellular lysates were collected with 150 μl reporter lysis buffer (Promega, Nepean, Canada) and cell lysis buffer and were assayed for luciferase activity and β-galactosidase activity immediately with the Luciferase Assay and β-Galactosidase Enzyme Assay Systems (Promega). Luminescence was measured using a Lumat LB 9507 luminometer (EG&G, Berthold, Germany). β-Galactosidase activity was also measured and used to normalize for varying transfection efficiencies. Promoter activity was calculated as luciferase activity/β-galactosidase activity. A promoterless pGL2-Basic vector was included as a control in the transfection experiments.
Immunoblot analysis
An immunoblot assay was performed to identify the expression of ERα and ERβ in BG-1 cells. Thirty μg of total protein was run on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was immunoblotted using a mouse monoclonal antibody for ERα (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and ERβ (Abcam, Cambridge, MA, USA). The membrane was immunoblotted using the actin antibody (Santa Cruz Biotechnology). To investigate the effect of xenoestrogen on activation of MAPK, approximately 1 × 10 6 cells were washed twice with ice-cold PBS and lysed in 100 μl of ice-cold RIPA buffer (containing 1 × PBS [pH 7.4], 1% NP 40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/ml phenylmethylsulfonyl fluoride, 30 mg/ml aprotinin and 10 mg/ml leupeptin) for 15 min on ice. The protein concentration was determined using the Bradford assay (Bio-Rad Laboratories, Mississauga, ON, Canada). The protein solution was then subjected to electrophoresis on a 10% SDS-PAGE and electrotransferred to a nitrocellulose membrane (Hybond C; Amersham Pharmacia Biotech, Oakville, ON, Canada). The membrane was immunoblotted with a rabbit polyclonal antibody for phosphorylated p38 MAPK (Biosource International, Camarillo, CA, USA), a mouse monoclonal antibody for phosphorylated extracellular signal-regulated kinase ERK 1/2 (New England Biolabs, Pickering, ON, Canada) and a protein molecular marker (New England Biolabs). After washing three times with TBS-T (0.1% Tween-20 in TBS) for 15 min, the signals were detected with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech) and were visualized using an ECL chemiluminescent system (Amersham Pharmacia Biotech). Alternatively, the membrane was probed with a mouse monoclonal p38 MAPK antibody (Biosource International) and pan ERK1/2 (New England Biolabs), which detects the total p38 MAPK and ERK1/2 levels, respectively.
Thymidine incorporation assay
A proliferation assay was performed using the [ 3 H]thymidine incorporation assay as previously described [21] . Briefly, BG-1 cells (4 × 10was treated with vehicle. The cells were precipitated with 0.5 ml trichloroacetic acid (10%) for 20 min at 4 C. The precipitate was washed in methanol twice and solubilized in 0.5 ml sodium hydroxide (0.1 N). The radioactivity was measured in a Tri-Carb Liquid Scintillation Analyzer (Model 2100TR; Packard Instrument Com., Meriden, CT, USA).
Data analysis
Data are presented as means ± SD. The data were analyzed by ANOVA followed by Tukey's multiple comparison test. P<0.05 was considered statistically significant.
Results
Confirmation of expression of ERα and ERβ in BG-1 cells
Since the ovarian adenocarcinoma cell line BG-1 is well known for its expression of ERα [22] , we first confirmed expression of ERα by Western blot analysis using an antibody targeting ERα in BG-1 cells. ERα is expressed in BG-1 cells, but is not expressed in the ERα-negative ovarian cancer cell line A2780 (Fig. 1) . We further confirmed the expression of ERβ in BG-1 cells and demonstrated that ERβ protein is also expressed in BG-1 cells.
Proliferative effect of EDCs on ovarian cancer cells
To determine the effect of E2 and EDCs on cell proliferation, BG-1 cells were treated with increasing doses of E2 and EDCs. Treatment with EDCs (10 -9 , 10 -8 , 10 -7 , 10 -6 and 10 -5 M) for 24 h resulted in a significant increase in cell proliferation at certain concentrations in a dose-dependent manner compared with the control ( Fig. 2A-E ). An increasing effect on cell proliferation was shown in the treatments with OP (over 10 nM) and NP (over 100 nM) as demonstrated in Figs , 10 -9 and 10 -7 M concentrations of E2 (Fig. 2E) . These results indicate that the EDCs induced an estrogenic effect in terms of stimulation of cell growth as E2 did in an E2-dependent ovarian cancer cell line.
To investigate the relevance of the estrogen-induced signal pathway in the cell proliferation, the cells were pretreated with ICI 182780 (ICI; 0.1 μM), an ERα and ERβ antagonist, for 20 min and were then treated with EDCs (10 -5 M) or E2 (10 -7 M). ICI 182780 pretreatment reversed E2-induced cell proliferation in these cells as seen in Fig. 3 . In addition, pretreatment with ICI 182780 significantly attenuated EDC-induced cell proliferation (Fig. 3) . These results suggest that the ER pathway is involved in EDC-induced cell proliferation in this estrogen-responsive cell line, BG-1.
Effect of EDCs on ERE activity
The ability of EDCs to activate ER-mediated transcription in BG-1 cells was further measured. The cells were transfected with the reporter plasmid ERE-tk-Luc and then treated with BPA, MXC, OP and NP at two increasing concentrations (10 -6 and 10 -5 M) and E2 (10 -7 M) as a positive control. Under these conditions, BPA stimulated the transcriptional activity of ERE in a dose-dependent manner (Fig. 4A ). OP and NP also increased ERE activity at similar level for ERE recruitment as that observed in BPA , but their effects do not appear to be dose-dependent as seen in Fig. 4A . Although a high concentration of MXC (10 -5 M) induced significant ERE activity, treatment with MXC produced much less ERE activity compared with the other EDCs. These results suggest that EDCs, similar to E2, have stimulating effects on ERE activity and activate the ER-mediated pathway at the transcriptional level. To further confirm that the EDC-induced effect on the activity of ERE is mediated via ERs, the cells were pretreated with ICI 182780 (0. 
Activation of MAPK by BPA
To investigate whether EDCs induce activation of mitogen-activated protein kinase (MAPK) in ovarian cancer cells, BG-1 cells were treated with increasing concentrations of BPA for 15 min. The phosphorylation of ERK1/2 and p38 was examined using antibodies targeting phosphorylated-ERK1/2 (P-ERK1/2) and phosphorylated-p38 (P-p38). Treatment with BPA at increasing concentrations induced activation of ERK1/2 and p38 MAPK in a dose-dependent manner and maximally increased level was observed at 1 μM (Fig. 5) . The total-ERK1/2 (T-ERK1/2, activated plus inactivated forms) and total-p38 levels were not affected by treatment with BPA. These results indicate that BPA induced the activation of ERK1/2 and p38 via a non-genomic pathway (within 15 min) in the ovarian cancer cells as shown in Fig. 5 .
Effect of BPA-induced MAPK activation on cell proliferation
To further elucidate the relevance of the ERK1/2 and p38 signaling pathways in xenoestrogen-and E2-induced cell growth of BG-1 cells, specific inhibitors, PD98059 (an MEK inhibitor) or SB203580 (a p38 inhibitor), were added 1 h prior to E2 or BPA treatment in a dose-dependent manner. Treatment with PD98059 or SB203580 alone at the doses of 10 these inhibitors at these doses resulted in stimulation of cell growth in BG-1 cells that was similar to that of the BPA alone treatment (Fig. 6 ). Co-treatment of BG-1 cells with PD98059 or SB203580 at a high concentration (10 -4 M) resulted in a non-specific reduction in cell growth compared with the untreated controls as shown in Fig. 6 .
Discussion
EDCs are considered to be xenoestrogens that mimic the effect(s) of estrogen, but a previous study demonstrated that some EDCs do not act through ERs, suggesting that a non-genomic effect is part of the mechanism of EDCs [23] . In addition, it has been reported that ERs are not involved in MXC-induced mRNA expression [14] . To investigate whether EDCs act through ER-ERE complex , we transiently transfected BG-1 cells with an EREluciferase reporter construct. As expected, treatment with E2 and BPA increased the transcriptional activity of ERE in a dose-dependent manner, and treatment with MXC had less effect on ERE activity compared with the other treated groups. OP and NP also increased ERE activity significantly, but did not show a dosedependent response, indicating that the level of EDC-induced EREactivity and the mechanism involved in EDC-induced ERE activity varies in different types of EDCs. Subsequently, we further investigated the direct involvement of ERs in EDC-induced ERE activation. Pretreatment with ICI 182780 completely abolished E2, BPA, OP and NP-induced ERE activity in BG-1 cells, suggesting that EDC-induced ERE promoter activity appears to be mainly mediated by ER-ERE complex in ovarian cancer cells.
Previous reports have also shown that EDCs might present human health risks and result in cell transformation, which may increase the risk of cancer incidence [3, 4, 8] . Furthermore, EDCs, i.e., BPA, OP, NP and MXC, are known to exhibit estrogenic activities and increase the growth of ovarian cancer cells [24] . In order to examine whether these EDCs have a proliferative effect on ovarian cancer cells, an E2-dependent ovarian cancer cell line, BG-1 cells, was treated with EDCs. Treatment with BPA, OP, NP and MXC increased cell growth in these cells. These results are consistent with the previous reports showing that E2 and EDCs induced cell growth in BG-1 cells [25] . However, no significant difference was observed in the groups of BPA, MXC, OP and NP at lower doses compared to E2-treated group, suggesting that they weakly mimic the effect of E2 activity on cell proliferation in ovarian cancer cells due to the lower binding affinity of EDCs to ERs (1000-10,000-fold) than E2 [26, 27] . ERs account for most of the EDCinduced mechanism causing endocrine-related disorders [28] , suggesting that ERs are involved in the EDC-induced growth in ovarian cancer cells. ERs, nuclear transcription factors, play an important role in mediating the genomic action of the steroid hormone E2 [29] . It has been reported that EDCs exert their actions genomically [30] or non-genomically [31] . It has also been reported that ERs in the plasma membrane are involved in the nongenomic effect of E2 [32] and that ERα mediates the non-genomic signaling pathway of E2 in an ERα positive cell line, BG-1 [33] . To investigate whether ERs are mediated in EDC-induced cell proliferation in ovarian cancer cells, the cells were pretreated with ICI 182780, an estrogen antagonist, prior to BPA, OP, NP and MXC treatment. Pretreatment with ICI 182780 significantly blocked EDC/E2-induced proliferation in BG-1 cells.
The expression of ERα and ERβ, two types of ERs, is different in most tissue types [34] , and these two receptors differentially activate target genes under different circumstances [35] . It is known that ERα accounts for the main mRNA expression of ERs in ovarian cancer cell lines. On the other hand, ERβ is dominantly expressed in normal ovaries [36] and is involved in induction of apoptosis or anti-tumoral effects in ovarian cancer cells [37] . Previous studies indicate that the EDC-induced estrogenic effect is mediated through ERα in an animal model [38] , suggesting that high concentrations of EDCs may increase cell growth by binding to ERα. However, further research is required to clarify the precise roles of ERα and ERβ in EDC-induced cell proliferation.
In the previous studies, BPA, OP and NP induced activation of ERK1/2 in MCF-7 cells [39] . A recent study indicated that E2 induced activation of p38 via non-genomic action [40] . However, there is little information available concerning the non-genomic effect of EDCs on ovarian cancer cells, and the issue of whether EDCs exert a non-genomic effect in ovarian cancer cells remains obscure. Thus, the MAPK activation was examined by immunoblot analysis using a phospho-specific ERK1/2 and p38 MAPK antibody following treatment with BPA. Treatment with BPA induced the activation of ERK1/2 and p38 in a dose-dependent manner, suggesting that a non-genomic effect may also be involved in EDC-induced cellular responses in ovarian cancer cells. However, activation of ERK1/2 and p38 MAPK appears to be decreased at high concentration of BPA (10 μM), suggesting that BPA might be involved in induction of MAPK phosphatase at this concentration. To elucidate the signaling pathway involved in this increasing proliferation as a result of EDCs, BG-1 cells were pretreated with specific inhibitors of MEK (PD98059) and p38 MAPK (SB203580) in a dose-dependent manner and were then treated with E2 or BPA. Treatment with PD98059 or SB203580 alone reduced cell proliferation in a dose dependent manner due to the blocking of MAPK activation. However, inhibition of MAPK activation by these inhibitors does not seem to affect BPA or E2-induced cell proliferation since treatment with EDC/E2 in the presence of these inhibitors increased cell proliferation compared with the groups treated with PD98059 or SB203580 alone at all concentrations. These results suggest that activation of ERK1/2 and p38 MAPK is not involved in stimulation of E2 or EDC-induced cell growth in estrogen-responsive ovarian cancer cells. Further research is necessary to explain the possible role of the EDCinduced MAPK activation in ovarian cancer cells.
Based on the results presented herein, EDC-induced ovarian cancer cell growth is mediated by ERs. In addition, ERE activation is involved in EDC-induced ER activity, suggesting that EDCs may share the components of a common pathway with E2 to induce cell proliferation; however, EDC-activated MAPK is unlikely to be involved in EDC-induced cell proliferation in estrogen-responsive ovarian cancer cells, BG-1.
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